SIBO: The Bacteria Stealing Your Breakfast
The small intestine is supposed to be relatively sterile. The large intestine — the colon — is a microbial metropolis, hosting trillions of bacteria that ferment fibre, produce vitamins, and maintain the mucosal immune system. The small intestine, upstream, is where you actually absorb your nutrients: iron, B12, folate, fat-soluble vitamins, amino acids, sugars. It needs to be relatively clear of bacteria for this to work. A muscular wave called the migrating motor complex (MMC) sweeps through the small intestine between meals, pushing bacteria downstream to the colon where they belong.
When this system fails — when bacteria colonise the small intestine in significant numbers — they eat your food before you absorb it. They ferment carbohydrates that should have been absorbed as glucose, producing hydrogen, methane, and hydrogen sulfide gas. They consume B12 and iron. They damage the intestinal lining, impairing absorption of everything else. The result is nutrient deficiency despite adequate dietary intake, bloating and pain after every meal, and — because your mitochondria need those nutrients to produce energy — fatigue.
This is Small Intestinal Bacterial Overgrowth (SIBO), and in ME/CFS patients it is probably the single most common treatable contributor to fatigue that is being systematically overlooked.
1 Why ME/CFS patients are sitting ducks
The migrating motor complex is controlled by the vagus nerve. The vagus nerve is dysfunctional in ME/CFS. This is not speculation — autonomic testing consistently shows impaired vagal tone in ME/CFS patients ((Newton et al. 2007); (Beaumont et al. 2012)).
The MMC fires during fasting — between meals and during overnight sleep — sweeping the small intestine clean approximately every 90 minutes. When vagal control of gut motility is impaired, MMC frequency drops. The cleaning cycle slows. Bacteria that would normally be swept to the colon accumulate in the small intestine. The longer the vagal dysfunction persists, the greater the overgrowth.
ME/CFS patients also tend toward reduced physical activity (because activity causes PEM), which independently slows gut motility. Many take medications that further reduce motility: opioids for pain, anticholinergics for various symptoms, proton pump inhibitors that reduce stomach acid (one of the body’s first-line defences against small intestinal colonisation).
The setup is a perfect storm: impaired vagal tone + reduced activity + motility-slowing medications + reduced gastric acid = an open door for SIBO.
2 Three types of SIBO, three different problems
SIBO is not one condition. The gas produced by the overgrown bacteria determines the symptom profile and the treatment.
Hydrogen-dominant SIBO is the most common type. Bacteria ferment carbohydrates and produce hydrogen gas. Symptoms are primarily diarrhoea-predominant: bloating, urgency, loose stools, abdominal cramping after meals. The hydrogen itself is relatively benign — it’s the mechanical and osmotic consequences of bacterial fermentation that cause symptoms.
Methane-dominant SIBO (increasingly called IMO — intestinal methanogen overgrowth) is caused by archaea (Methanobrevibacter smithii, primarily) that consume hydrogen and produce methane. Methane directly slows gut transit — it inhibits smooth muscle contraction in the intestinal wall (Pimentel et al. 2006). The result is constipation-predominant symptoms: bloating, infrequent stools, straining, a sensation of incomplete evacuation. Methane SIBO creates a vicious cycle: the methane slows motility, which worsens the overgrowth, which produces more methane.
Hydrogen sulfide-dominant SIBO is the newest recognised type. Sulfate-reducing bacteria (Desulfovibrio, Bilophila, Fusobacterium) consume hydrogen and produce H₂S. This variant deserves its own discussion — and its own article in this series — because H₂S is a mitochondrial poison. It inhibits cytochrome c oxidase (Complex IV of the electron transport chain) at the same binding site as cyanide. A patient with H₂S-dominant SIBO is not just malabsorbing nutrients — their gut bacteria are producing a compound that directly suppresses mitochondrial energy production.
3 What SIBO steals
The nutrient theft is specific and devastating for ME/CFS patients:
Iron. Bacteria in the small intestine consume dietary iron and damage the duodenal mucosa where iron is absorbed. A patient can eat adequate dietary iron and still be functionally iron-depleted — not because of dietary deficiency but because of competitive consumption and absorptive failure. Their ferritin drops for reasons that a dietary history won’t reveal.
Vitamin B12. Bacteria consume B12 before it reaches the terminal ileum, where absorption occurs. B12 deficiency from SIBO can produce fatigue, neuropathy, and cognitive dysfunction — symptoms that in an ME/CFS patient are attributed to the disease itself rather than to a treatable cause.
Fat-soluble vitamins (A, D, E, K). Bacterial deconjugation of bile acids in the small intestine impairs fat absorption, and with it the absorption of fat-soluble vitamins. Vitamin D deficiency in an ME/CFS patient may not be from insufficient sun exposure — it may be from malabsorption that nobody tested for.
Calories. Bacterial fermentation of carbohydrates in the small intestine diverts caloric substrate that should have fuelled the patient. The patient feels exhausted after eating because the meal triggered bacterial fermentation rather than nutrient absorption. The bloating, gas, and post-prandial fatigue are not “functional” — they are the result of bacteria consuming the meal first.
4 Diagnosis: imperfect but available
The standard diagnostic test is the lactulose or glucose breath test. The patient drinks a sugar solution, and exhaled hydrogen and methane are measured at intervals over 90-120 minutes. A rise in hydrogen or methane before the solution reaches the colon (typically within 90 minutes) suggests bacterial fermentation in the small intestine.
The test has well-known limitations. Sensitivity is moderate — studies report 60-70% — and specificity depends on interpretation criteria that vary between laboratories (Rezaie et al. 2017). False negatives are common, particularly for H₂S-dominant SIBO, which was not measurable on standard breath tests until recently (the trio-smart test now measures all three gases).
The glucose breath test is more specific but less sensitive — glucose is absorbed quickly in the proximal small intestine, so it may miss distal SIBO. The lactulose test is more sensitive but less specific — lactulose reaches the colon in everyone, creating a baseline rise that can be difficult to distinguish from a small intestinal signal.
Despite these limitations, a positive breath test in a symptomatic ME/CFS patient is clinically actionable. And a negative test doesn’t rule out SIBO — it may justify empirical treatment if the clinical picture is strongly suggestive.
5 Treatment: effective but recurrent
The standard treatment for hydrogen-dominant SIBO is rifaximin (Xifaxan), a non-absorbed antibiotic that acts locally in the gut. It is well-tolerated, has minimal systemic absorption, and is effective in approximately 50-70% of cases at standard dosing (Pimentel et al. 2011).
Methane-dominant SIBO requires combination therapy — typically rifaximin plus neomycin or metronidazole — because the archaea responsible for methane production are not adequately targeted by rifaximin alone.
H₂S-dominant SIBO treatment is less standardised. Bismuth subsalicylate has some efficacy against sulfate-reducing bacteria. Dietary sulfur restriction (reducing garlic, onion, cruciferous vegetables, eggs, high-sulfur supplements like NAC and alpha-lipoic acid) reduces substrate availability.
The elemental diet — a liquid nutrition formula that is absorbed in the proximal small intestine, leaving nothing for bacteria to ferment — is effective in approximately 80% of cases but is difficult to sustain for the required 2-3 weeks and is expensive.
The recurrence problem. This is the central challenge. SIBO responds to treatment, but if the underlying motility dysfunction is not addressed, it returns. In ME/CFS patients, the vagal dysfunction that caused the SIBO is part of the disease. The SIBO is a downstream consequence, not the root cause. Treatment provides relief — sometimes dramatic relief — but maintenance is required.
Prokinetic agents (low-dose erythromycin, prucalopride) stimulate the MMC and reduce recurrence. Meal spacing — allowing 4-5 hours between meals to permit MMC cycling — is a simple non-pharmacological intervention that many ME/CFS patients find helpful.
6 Why this matters for ME/CFS specifically
A patient with ME/CFS and untreated SIBO has two energy drains running simultaneously: the disease itself and the bacterial parasitism in their small intestine. The SIBO is stealing nutrients that the compromised mitochondria need. It’s producing H₂S that further inhibits those mitochondria. It’s driving intestinal inflammation that activates the immune system, consuming yet more energy. And it’s causing post-prandial symptoms that the patient and their doctor attribute to “just ME/CFS.”
Treating the SIBO doesn’t cure the ME/CFS. But it removes a significant, treatable burden from a system already at its limit. Patients who have SIBO successfully treated report meaningful improvements in fatigue, cognitive function, and post-prandial symptoms — not because ME/CFS is caused by SIBO, but because SIBO was making everything worse.
The question to ask is not “could SIBO be causing all of this?” It rarely is. The question is “could SIBO be making all of this 20-30% worse?” In a patient whose energy margin is measured in percentage points, 20-30% is the difference between housebound and able to leave the house.
Every ME/CFS patient with gastrointestinal symptoms — bloating, post-prandial fatigue, food intolerances, alternating bowel habits — should be tested for SIBO. The breath test costs under €100. The treatment, if positive, is a two-week course of a well-tolerated antibiotic. The potential return on a €100 test and a €50 prescription is a measurable improvement in the energy budget of a patient who cannot afford to waste a single percent (Loth 2026).